Agilent will provide service to the customers of NimbleGen microarray as Roche is phasing out
Singapore: Agilent Technologies and Roche announced the signing of an exclusive agreement to provide continued service to the customers of NimbleGen microarray as Roche is phasing out its NimbleGen array production and services.
NimbleGen microarrays are used for several research applications, including comparative genomic hybridization, chromatin immunoprecipitation-on-chip, DNA methylation and gene expression and can be transitioned to Agilent arrays with minimal disruption.
The similarities of the technologies and products from both companies provide an optimal transition path and the ability to run Agilent microarrays on the NimbleGen MS 200 Microarray Scanner.
Dr Dan Zabrowski, head, Roche Applied Science, said that, "With Agilent as a leading global supplier of microarray technology, we are convinced researchers will be provided with the highest compatibility to NimbleGen products and services, and believe that they will continue to receive the exceptional service and support they have come to expect."
Mr Robert Schueren, VP and general manager, genomics systems division, Agilent, said that, "Our field service personnel are working directly with individual researchers to help convert their NimbleGen designs, and they will continue to provide enhanced service and support throughout the transition period and beyond. Additionally, Agilent is also enabling customers to read their arrays on NimbleGen scanners, eliminating the need to invest in capital equipment."
